Parkinson’s Drug Misses Again But Roche Not Giving Up Yet
The Phase IIb failure was expected, but Roche believes consistent trends towards efficacy could be confirmed with ongoing open-label studies, leaving life in the program yet.
The Phase IIb failure was expected, but Roche believes consistent trends towards efficacy could be confirmed with ongoing open-label studies, leaving life in the program yet.